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Abstract Syntheses and biological activities of imidazo-,
pyrimido- and diazepino[2,1-f]purinediones containing N-al-
kyl substituents (with straight, branched or unsaturated chains)
are described. Tricyclic derivatives were synthesized by the
cyclization of 8-bromo-substituted 7-(2-bromoethyl)-, 7-(3-
chloropropyl)- or 7-(4-bromobutyl)-theophylline with primary
amines under various conditions. Compound 22 with an
ethenyl substituent was synthesized by dehydrohalogenation
of 9-(2-bromoethyl)-1,3-dimethyltetrahydropyrimido[2,1-f]
purinedione. The obtained derivatives (5–35) were initially
evaluated for their affinity at rat A1 and A2A adenosine
receptors (AR), showing moderate affinity for both adenosine
receptor subtypes. The best ligands were diazepinopurinedione
28 (Ki=0.28 μM) with fivefold A2A selectivity and the non-
selective A1/A2A AR ligand pyrimidopurinedione 35 (Ki A1=
0.28 μM and Ki A2A=0.30 μM). The compounds were also
evaluated for their affinity at humanA1, A2A, A2B and A3 ARs.
All of the obtained compounds were docked to the A2A AR X-
ray structure in complex with the xanthine-based, potent aden-
osine receptor antagonist—XAC. The likely interactions of
imidazo-, pyrimido- and diazepino[2,1-f]purinediones with
the residues forming the A2A binding pocket were discussed.
Furthermore, the new compounds were tested in vivo as
anticonvulsants in maximal electroshock, subcutaneous
pentylenetetrazole (ScMet) and TOX tests in mice (i.p.).
Pyrimidopurinediones showed anticonvulsant activity mainly
in the ScMet test. The best derivative was compound 11,
showing 100 % protection at a dose of 100 mg/kg without
symptoms of neurotoxicity. Compounds 6, 7, 8 and 14 with
short substituents showed neurotoxicity and caused death. In
rat tests (p.o.), 9 was characterized by a high protection index
(>13.3). AR affinity did not apparently correlate with the
antiepileptic potency of the compounds.
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([3H]CCPA) [3H]2-chloro-N6-cyclopentyladenosine
([3H]PSB-603) [3H]8-(4-(4-(4-chlorophenyl)piperazine-
1-sulfonyl)phenyl)-1-propylxanthine
([3H]PSB-11) [3H]2-phenyl-8-ethyl-4-methyl-(8R)-4,5,7,
8-tetrahydro-1H-imidazo[2,1-i]purine-5-one
([3H]MSX-2) [3H]1-propargyl-3-(3-hydroxypropyl)-7-
methyl-8-(m-methoxystyryl)xanthine)
IR Infrared
MES Maximal electroshock
NINDS National Institute of Neurological Disorders
and Stroke
NMR Nuclear magnetic resonance
PI Protection index
PDB Protein data bank
PSB-36 1-Butyl-3-hydroxypropyl-8-
noradamantylxanthine
RMSD Root mean square deviation
ScMet Subcutaneous pentylenetetrazol
TLC Thin layer chromatography
UV Ultra-violet
XAC Xanthine amine congener
Introduction
Adenosine, a major constituent of nucleic acids, which con-
sists of the purine base adenine linked to the ribosemoiety, has
important and diverse effects on many biological processes.
Some of the physiological actions of adenosine include effects
on heart rate and atrial contractility, vascular smooth muscle
tone, release of neurotransmitters, lipolysis, renal function and
white blood cell functions [1, 2].
Four adenosine receptor (AR) subtypes are known,A1, A2A,
A2B and A3, all of which were cloned and pharmacologically
characterized. The A2A and A2B receptors are positively
coupled to adenylyl cyclase, while A1 and A3 adenosine re-
ceptors cause inhibition of cAMP formation. Adenosine acts
via these different receptor subtypes, the affinity to which
ranges from nanomolar (“high affinity” A1, 3–30 nM; A2A
1–20 nM) to micromolar (“low affinity” A2B, 5–20 μM;
A3>1 μM) [3, 4]. These receptors belong to the large super-
family of G protein-coupled receptors [2].
Adenosine A1 receptors are ubiquitously expressed, e.g.
in the central nervous system (CNS), especially in the brain,
with high levels being expressed in many regions. The
distribution of adenosine A2A receptors is wide ranging
but restricted, including lymphocytes, platelets, brain stria-
tum, vascular smooth muscle and endothelium [2].
The prototypical antagonists of the A1 adenosine receptor
are the xanthines: theophylline and caffeine. Natural xanthines
are non-specific adenosine antagonists. They are not selective
for any of the adenosine receptor subtypes and have low
affinity for the A1 receptor. Due to their CNS-stimulating
effects, A1 adenosine receptor selective antagonists have been
proposed as cognition enhancers for the treatment of demen-
tias, such as Alzheimer’s disease. These receptors have been
shown to be involved in sedative, antiseizure and anxiolytic
effects. New potential indications are being discovered and
investigated: in heart (for the treatment of cardiac arrhythmias
and oedemas and as positive inotropic and cardiac protectants),
in kidney (for oedemas and nephritis treatment), in lung (for
asthma, oedema and lung protection) and in CNS (for depres-
sion, stress and coma) diseases. A1 AR antagonists are being
investigated as antihypertensives and potassium-saving di-
uretics with kidney protective effects, for the treatment of
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depression and asthma and for the prevention of ischemia-
induced injuries [5–7].
In the last years, numerous studies have confirmed the
ability of A2A adenosine receptor antagonists to prevent neu-
rodegenerative diseases such as Parkinson’s and Alzheimer’s
diseases, ischemic brain damage and, recently, epilepsy and
sensorimotor disorders (restless legs syndrome—RLS)
[8–14]. Methylxanthines such as theophylline and caffeine
have been known to enhance locomotor activity; however,
these compounds are non-selective antagonists and have weak
affinity for A2A AR.
Our efforts were directed towards the development of new
selective xanthine adenosine receptor ligands. Our main inter-
est has focussed on the investigation of tricyclic xanthine de-
rivatives [15–19]. The so far most active compounds are
shown in Fig. 1. The most potent A1 AR ligands were found
among 1,3-dipropyl-substituted benzylpyrimidopurinediones
(I, II) [17], while A2A adenosine receptor ligands were 1,3-
Table 1 Structures of the tested imidazo-, pyrimido- and diazepino[2,1-f]purinediones (5–35)
N
N N
N
N
CH2
O
O
R1
R1
R
n
Cpd R R1 n Cpd R R1 n
5 H CH3 2
6 CH3 CH3 2 22 CH3 2
7 CH3 2 23 CH3 2
8 CH3 2 24 CH3 2
9 CH3 2 25 H CH3 3
10 CH3 2 26 CH3 3
11 CH3 2 27 CH3 3
12 CH3 2 28 CH3 3
13 CH3 2 29 CH3 3
14 CH3 2 30 CH3 3
15 CH3 2 31 CH3 3
16 CH3 2 32 CH3 3
17 CH3 2 33 H CH3 1
18 CH3 2 34 CH3 1
19 CH3 2 35 C3H7 2
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dimethyl-substituted aryl- (III, IV) [16] cycloalkyl- (V) [19]
and phenalkylpyrimidopurinediones (VI) [18] (Fig. 1). Several
of the most active ligands at adenosine A2A AR (e.g. III, IV
and VI) [20] were demonstrated to exhibit antiparkinsonian
effects. Among pyrimidopurinediones, compounds were
found which displayed anticonvulsant properties—protective
activity in subcutaneous pentylenetetrazole (ScMet) or in
maximal electroshock (MES) and ScMet test; however,
the mechanism of this action was not clear [16, 19].
As a continuation of our search for potent adenosine A1 and
especially A2A receptor ligands among cycloalkyl annelated
xanthines, we have developed a new series of imidazo-,
pyrimido- and diazepino[2,1-f]purinedione derivatives
possessing aliphatic substituents (open congeners of cycloalkyl
derivatives) in the annelated ring, e.g. alkyl, alkynyl and
alkenyl chains. The compounds turned out to be selective A1
or A2A AR antagonists with moderate, submicromolar affinity
as shown by radioligand binding studies at native rat receptors.
Investigated compounds were examined also for A2B and A3
AR affinity at human recombinant AR. Additionally, the most
active compounds were evaluated for affinity at human recom-
binant A1 and A2A AR affinity. Molecular modelling studies
were performed to discuss affinity of the compounds through
the docking onto the active sites of the A2A adenosine receptor
model. Investigated compounds were examined for their anti-
convulsant activity as well.
Results and discussion
Chemistry
The synthesis of tricyclic imidazo-, pyrimido- and
diazepinopurinediones (Table 1) was accomplished as
shown in Fig. 2. As starting material for 1,3-dimethyl-
imidazo[2,1-f]purinediones (33, 34), 7-(2-bromoethyl)-8-
bromotheophylline (1) was used, the preparation of which
had been described by Caccacae [21]. In our laboratory, a
modified procedure was developed using a two-phase catal-
ysis method [16]. The other starting compounds, 7-(3-
chloropropyl)-8-bromotheophylline (2) for 1,3-dimethyl-
pyrimido[2,1-f]purinediones (5–24) and 7-(4-bromobutyl)-
8-bromo-theophylline (3) for 1,3-dimethyl-diazepino[2,1-f]
purinediones (25–32), were obtained as previously described
[22, 23]. 1,3-Dipropyl-7-(3-chloropropyl)-8-bromoxanthine
(4) [16, 17] was used as starting material for the synthesis of
pyrimido[2,1-f]purinedione (35). The cyclization reaction
with amines possessing straight, branched or unsaturated
chains was carried out under various conditions (excess of
amine, solvent and different reaction time). The synthesis of
compounds 8, 9 and 23 was described previously [24], but
their structures had been confirmed only by UV spectra, and
pharmacological tes ts had not been performed.
Unsubstituted compounds 5, 25 and 33 were previously
synthesized in our group [25, 26] and were now subjected
to pharmacological tests to compare them with substituted
derivatives. Compound 22 with an ethenyl moiety was
obtained by dehydrohalogenation of 9-(2-bromoethyl)-1,3-
dimethyl-6,7,8,9-tetrahydropyrimido[2,1-f]purinedione (21)
[27] (formed from the appropriate hydroxy ethyl derivative
20 [28]) with ethanolic potassium hydroxide (Fig. 2). The
structures of the synthesized compounds were confirmed by
UV, IR and 1H NMR spectra: UV spectra showed a
bathochromic shift typical for 8-aminoxanthine derivatives
with λmax of about 300 nm [29]. The IR absorption bands
were typical of xanthine derivatives [30], and in the 1H NMR
spectra, the expected chemical shifts were observed. All
compounds were purified by recrystallization.
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X-ray structure analysis
Among derivatives with various alkyl substituents at
N(9) or (10) (Table 1), monocrystals of three of them—
10, 11 and 30—suitable for X-ray structure analysis
could be selected. The structures represent pyrimido-
(10 and 11) and diazepino- (30) purinediones with N1,
N3-dimethyl substituents at the xanthine nitrogen atoms.
They feature linear (pentyl and hexyl) or branched (iso-
pentyl) substituents at N(9) or (10). The description and
discussion of 10, 11 and 30 spatial properties are at-
tached in the supplementary section.
Pharmacology
All compounds were tested in vitro in radioligand binding
assays for affinity to A1 and A2A adenosine receptors in rat
cortical membrane and rat striatal membrane preparations,
respectively. The results are presented in Table 2. The non-
selective AR ligand caffeine, selective A2A AR antagonist
Preladenant (SCH420814) [31] and selective A1 AR
antagonist PSB-36 [31, 32] were included for comparison.
Examined compounds were additionally tested for affinity at
human recombinant A1, A2A, A2B and A3 receptors stably
expressed in Chinese hamster ovary (CHO) cells (Table 3).
Table 2 Affinities of imidazo-, pyrimido- and diazepino[2,1-f]purinediones at rat A1 and A2A adenosine receptors
Compound Adenosine A1 receptor (rat brain
cortical membranes) vs. [3H]CCPA
Adenosine A2A receptor (rat brain
striatal membranes) vs. [3H]MSX-2
A2AAR selectivity
A1/A2A
Ki ± SEM [μM] (% inhibition ± SEM
at 25 μM) (n=3)
Ki ± SEM [μM] (% inhibition ± SEM
at 25 μM) (n=3)
5 >25 (30±3 %) 5.22±0.90 >5
6 >25 (28±3 %) 4.30±0.67 >6
7 ≥25 (42±1 %) 2.65±0.65 >9
8 3.87±0.56 1.29±0.18 3
9 4.32±0.40 1.75±0.55 3
10 3.16±0.33 3.06±1.00 1
11 2.87±0.39 0.82±0.18 4
12 >25 (38±1 %) 4.95±1.32 >5
13 2.69±0.38 0.87±0.03 3
14 ≥25 (40±1 %) 4.64±0.85 >5
15 >25 (19±3 %) 8.87±2.04 >3
16 >25 (30±2 %) 5.37±0.32 >5
17 >25 (21±0.3 %) >25 (37±9 %) –
18 >25 (30±2 %) 2.38±0.81 >11
19 7.69±0.57 2.03±0.14 >4
22 >25 (30±5 %) >25 (47±3 %) –
23 4.40±0.42 2.62±0.72 2
24 ≥25 (46±7 %) 7.40±2.52 >3
25 >25 (33±3 %) >25 (38±9 %) –
26 2.24±0.90 (71±2 %) 1.73±0.41 1
27 1.24±0.18 0.85±0.08 2
28 1.53±0.08 0.28±0.02 6
29 ≥25 (49±0 %) 3.82±0.23 –
30 >25 (30±1 %) 3.51±1.19 >7
31 1.33±0.22 2.27±0.43 0.6
32 1.88±0.40 2.26±0.79 1
33 >25 (12±4 %) >25 (45±2 %) –
34 1.12±0.11 (50.77±2.59 %) 3.80±1.30 0.3
35 0.28±0.02 0.30±0.09 1
Caffeine[19] 18.8±5.6 32.8±0.09
Preladenant (SCH420814) 0.0687±0.0087 0.000661±0.000126 104
PSB-36 0.000368±0.000021 0.371±0.049 0.001
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The following radioligands were used: [3H]2-chloro-N6-
cyclopentyladenosine ([3H]CCPA) for A1, [
3H]1-propargyl-
3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)xanthine
([3H]MSX-2) [33, 34] for A2A, [
3H]PSB-603 [3H]8-(4-(4-(4-
chlorophenyl)piperazine-1-sulfonyl)phenyl)-1-propylxanthine
[35] for A2B and [
3H]2-phenyl-8-ethyl-4-methyl-(8R)-4,5,7,8-
tetrahydro-1H-imidazo[2,1-i]purine-5-one ([3H]PSB-11)
[36] for A3 binding studies.
Tricyclic xanthine derivatives, previously obtained in our
laboratory, showed anticonvulsant activity [15–18]. Therefore,
compounds 5–35 were evaluated in vivo as potential anticon-
vulsants by the ADP (Antiepileptic Drug Development Pro-
gram of the National Institute of Neurological Disorders and
Stroke NINDS) according to the Antiepileptic Screening Pro-
ject. Compounds were injected intraperitoneally as a suspen-
sion in 0.5 % methylcellulose into the mice and evaluated in
the preliminary screenings with at least three dose levels (30,
100 and 300mg/kg at 0.5- and 4-h time periods). Phase I of the
evaluation included three tests: MES, ScMet seizure tests and
the rotorod test for neurological toxicity (TOX). The tests were
described in detail by Stables and Kupferberg [37–39].
The MES test is a model for generalized tonic–clonic
seizures and identifies compounds which prevent seizure
spread. The ScMet is a model to test compounds that raise
seizure threshold. The minimal motor impairment was mea-
sured by the rotorod test. The results are given in Table 4.
Table 3 Affinities of imidazo-, pyrimido- and diazepino[2,1-f]purinediones at human recombinant A1, A2A, A2B and A3 adenosine receptors
Compound Adenosine A1 receptor (human
recombinant) vs. [3H]CCPA
Adenosine A2A receptor
(human recombinant) vs.
[3H]MSX-2
Adenosine A2B receptor
(human recombinant) vs.
[3H]PSB-603
Adenosine A3 receptor
(human recombinant) vs.
[3H]PSB-11
Ki ± SEM [μM] (% inhibition ±
SEM at 10 μM) (n=3)
Ki ± SEM [μM] (% inhibition ±
SEM at 10 μM) (n=3)
Ki ± SEM [μM] (% inhibition ±
SEM at 10 μM) (n=2)
Ki ± SEM [μM] (% inhibition ±
SEM at 10 μM) (n=2)
5 n.d. n.d. >10 (49±1 %) >10 (10±7 %)
6 n.d. n.d. >10 (6±2 %) >10 (3±3 %)
7 n.d. n.d. >10 (12±8 %) >10 (5±4 %)
8 n.d. n.d. >10 (1±2 %) >10 (10±3 %)
9 n.d. n.d. >10 (3±6 %) >10 (12±2 %)
10 n.d. n.d. >10 (−3±2 %) >10 (21±5 %)
11 3.80±0.91 2.07±0.47 >10 (9±5 %) >10 (39±1 %)
12 n.d. n.d. >10 (−4±3 %) >10 (8±1 %)
13 1.91±0.27 0.93±0.11 >10 (5±7 %) >10 (18±2 %)
14 n.d. n.d. >10 (−9±4 %) >10 (14±2 %)
15 n.d. n.d. >10 (0±3 %) >10 (17±1 %)
16 n.d. n.d. >10 (1±6 %) >10 (22±2 %)
17 n.d. n.d. >10 (3±7 %) ≥10 (43±4 %)
18 n.d. n.d. >10 (−3±5 %) >10 (32±2 %)
19 n.d. n.d. >10 (0±4 %) 2.57±0.53
22 >10 (21±7 %) >10 (29±8 %) >10 (1±3 %) >10 (11±2 %)
23 n.d. n.d. >10 (6±4 %) >10 (17±6 %)
24 n.d. n.d. >10 (29±5 %) >10 (11±2 %)
25 n.d. n.d. >10 (9±5 %) >10 (14±5 %)
26 n.d. n.d. >10 (6±5 %) >10 (12±3 %)
27 2.47±0.10 1.69±0.25 >10 (12±4 %) >10 (8±3 %)
28 4.13±0.58 1.10±0.16 >10 (10±7 %) >10 (23±3 %)
29 n.d. n.d. >10 (−4±6 %) >10 (2±4 %)
30 n.d. n.d. >10 (−1±3 %) >10 (27±0 %)
31 n.d. n.d. >10 (−1±6 %) >10 (22±3 %)
32 n.d. n.d. >10 (7±3 %) >10 (7±4 %)
33 n.d. n.d. >10 (17±8 %) >10 (9±3 %)
34 n.d. n.d. >10 (16±9 %) >10 (9±1 %)
35 0.60±0.03 1.39±0.21 1.32±0.23 0.66±0.02
Preladenant
(SCH420814)
0.295±0.010 0.000884±0.000232 >1 (25±1 %) >1 (35±1 %)
PSB-36 0.00397±0.00048 0.332±0.034 0.0486±0.0037 >1 (39±5 %)
n.d. not detected
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Table 4 Anticonvulsant activity and neurotoxicity of imidazo-, pyrimido- and diazepino[2,1-f]purinediones in mice (i.p.)
Compounda MESb ScMetb,c Toxicityb,c ASP
classd
0.25 h 0.5 h 1 h 4 h 0.25 h 0.5 h 1 h 4 h 0.25 h 0.5 h 1 h 4 h
5 3
6 30 (1/4) 300e 4
7 30 (1/5) 300f (4/4) 1
8 30 (1/5) 300f (2/4) 1
9 100 (1/3) 30 (1/4); 100 (4/5) 30 (1/4);
300g (4/4)
4
10 100 (1/3) 300 (1/1) 100 (3/8);
300g (4/4)
2
11 100 (5/5) 1
12 30 (1/5); 300h (1/5) 30 (1/4) 4
13 100 (3/5) 300 (2/4) 1
14 100 (4/5) 300f,g (4/4) 1
15 100 (1/3) 100 (5/5) 300g (4/4) 1
16 100 (3/3) 100 (5/5) 100 (1/3) 1
17 300 (4/5) 300i (1/1) 100 (1/8) 2
18 100 (1/5) 300 (5/5) 300 (1/1) 1
19 300 (1/1) 30 (1/5) 1
22 100 (3/5) 300 (1/4) 1
23 300g (1/4) 3
24 j, k 300g (4/4) 3
25 3
26 300 (4/4) 3
27 300 (3/4) 3
28 300f,g (3/4) 3
29
30 300 (1/4) 3
31 300 (1/1) 300 (1/1) l 100 (5/8) 2
32 300 (1/1) 300 (2/4) 2
33 300 (3/4)f 300 (1/1)g 3
34 100 (6/8)g,m;
300 (4/4)k
100 (1/4) 3
35 100 (2/8)n;
300 (3/4)n
300 (2/2)f
a Suspension in 0.5 % methylcellulose
b Doses of 30, 100 and 300 mg/kg. The figures in the table indicate the minimum dose whereby activity was demonstrated. The animals were
examined 0.5 and 4.0 h after injections were made. For compounds 9, 10 and 16, the response was measured after 0.25 h
c In anticonvulsant tests, figures, for example, 1/5 mean number of animals protected/number of animals tested, in toxicity test—number of animals
exhibiting toxicity/number of animals tested
d Classification is as follows: 1 anticonvulsant activity at 100 mg/kg or less, 2 anticonvulsant activity at 300 mg/kg, 3 lack of anticonvulsant activity
at 300 mg/kg, 4 neurotoxicity at dose 30 mg/kg
e Clonic seizures
f Death
g Unable to grasp rotorod
h Tonic extension
iMyoclonic jerks
j Death following tonic extension
k Death following clonic seizure
l Death following continuous seizure
mGroaming effect
n Popcorn effect
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Some compounds (9, 11, 13, 15, 16, 22 and 30) were also
administered orally to rats and examined in the MES, ScMet
screen and TOX test (Table 5). Compound 9was tested also in
the hippocampal binding model in rats to evaluate its ability to
prevent or modify both the expression and acquisition of focal
seizures [39] (Table 6). For two compounds (9 and 13), a
quantitative test in mice (i.p.) was made (ED50 and TD50
determination). The results of these experiments compared
with literature data for valproate [40] are collected in Table 7.
In vitro tests
Synthesized tricyclic xanthine derivatives displayed af-
finity towards both A1 and A2A ARs in radioligand
binding studies performed at rat brain membranes
(Table 2). The most active but not selective A1 AR
ligand was 1,3-dipropylpyrimidopurinedione (35). In
the group of diazepinopurinediones were found com-
pounds which displayed submicromolar affinity towards
adenosine A2A receptors. Diazepinopurinedione 28 (Ki=
0.28 μM) showed moderate A2A AR selectivity (about six-
fold). A2A AR ligands with submicromolar affinity were also
found among pyrimidopurinediones: compounds 11 and 13
displayed Ki values of 0.82 and 0.87 μM, respectively. N-
substituted derivatives displayed higher affinity than
unsubstituted analogues (5, 25 and 33). Elongation of the
straight N-alkyl substituents led to an increase in both A1
and A2A AR affinities in the group of diazepinopurinediones.
For pyrimidopurinediones, this tendency was not so obvious;
it was only observed at A1 AR. In the case of A2A AR, the
most active ones were compounds with 6 (comp. 11) and 3
(comp. 8) atom chains. Branched N-alkyl, especially α-
branched substituents, generally were not favourable for AR
affinity. In case of A1 AR ligands, such modifications led to a
loss of affinity (compounds 12, 14, 15, 16 and 18) or its
decrease (compound 19). A2A AR ligands were also sensitive
to these modifications; however, compounds with branched
N-alkyl substituents still showed micromolar affinity, and β-
branched derivative 13 was the most active one with
submicromolar affinity. Enlargement of the annelated ring
was favourable for both A1 and A2A AR activities.
Diazepinopurinediones with the same N-alkyl substituents as
pyrimidopurinediones were up to sixfold more potent (com-
pounds 9 and 28, and 8 and 27). An exception here was the N-
isopropyl derivative 34 which possesses a five-membered
annelated ring; however, there are only two members
of this group for comparison. Introduction of N1,N3-
dipropyl substituents into the xanthine core definitely
has favourable influence on A1 AR affinity of N-
alkylpyrimidopurinediones: compound 35 was 15-fold
more potent than its N1,N3-dimethyl analogue 9. Li-
gands with unsaturated N-substituents (22–24) displayed
only moderate A1 and A2A AR affinity.
Selected compounds are mainly those that were the most
active ones at the A2A AR (11, 13, 22, 27, 28 and 35) and
were also tested for affinity to human A1 and A2A receptors
Table 5 Anticonvulsant activity and neurotoxicity of selected compounds after oral administration (30 or 50 mg/kg) to rats
Compounda MESb,c ScMetb,c Toxicityd
0.25 h 0.5 h 1 h 2 h 4 h 0.25 h 0.5 h 1 h 2 h 4 h 0.25–4 h
9 50 (4/4) 50 (4/4) 50 (4/4) 10 (2/4) 10 (2/4) 10 (3/4) –
11 50 (1/4) –
13 30 (1/4) 30 (1/4) –
15 50 (1/4) 50 (1/4) 50 (2/4) 50 (2/4) –
16 30 (1/4) 30 (1/4) 30 (1/4) 50 (1/4) 50 (1/4) 50 (1/4) 50 (2/4) –
22 50 (1/4) 50 (1/4) –
30 30 (2/4) 30 (1/4) –
a Form—suspension in 0.5 % methylcellulose
b Doses of 10, 30 and 50 mg/kg
c Figures under doses indicate number of animals protected/number of animals tested
d The dash (−) indicates an absence of toxicity at maximum dose administration (50 mg/kg)
Table 6 Test results of com-
pound 9—preliminary
hippocampal binding screen
in rats (i.p)
aDose 100 mg/kg
bMinimal motor impairment
Rata,b Seizure pre-drug Score comp. 9 After discharge pre-drug Duration (SCCS)
Low High Low High Low High Low High
1 5 – 0 – 47 56 21 –
2 4 5 0 – 32 114 0 –
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(Table 3). Generally, the affinity at human recombinant A1
as well as A2A receptors was worse than that for native rat
receptors (in the range of 1.5—threefold lower affinity).
Only in the case of isobutylpyrimidopurinedione 13, the
affinity for the human A1 AR was better than that for the
rat receptor and almost equal for A2A AR.
Affinity to the human A2B and A3 receptors of all of the
investigated compounds was very weak; only the dipropyl
derivative 35 showed micromolar affinity at A2B AR and
submicromolar affinity to the human A3 AR. Only one
compound with a double-branched, long chain (19) from
the group of dimethyl derivatives showed affinity for A3 AR
in the micromolar range.
Two of the most potent rat and human A2A receptor
ligands (compounds 28 and 35) were investigated for their
functional properties using cAMP accumulation assay. They
were investigated for their potency to inhibit NECA-
induced cAMP accumulation in CHO cells expressing the
human A2A receptor (Fig. 3). The compounds clearly be-
haved as competitive antagonists as the concentration–re-
sponse curve of NECA was shifted to the right in a parallel
fashion in their presence. Kb values determined in living
CHO cells expressing the human adenosine A2A receptor
were well in accordance with Ki values determined in
radioligand binding studies at membrane preparations
of the same cell line. Owing to the structural similarity
of all compounds in this series, we suppose that they
are all antagonists.
Molecular modelling studies
In our previous molecular modelling studies on A1 and A2A
adenosine receptors, the comparison of rhodopsin- and β2-
adrenergic-based homologymodels through the docking stud-
ies was performed [41]. Since that time, a few X-ray structures
of A2A AR in complex with various ligands have been
reported in the Protein Data Bank [42, 43], among which
Table 7 Quantitative anticonvulsant activity and neurotoxicity of 9 and 13 and valproate in mice i.p
Compound TD50
a ED50 MES
b ED50 ScMet
c PId
MES ScMet
9 137.34 (184.27–222.9) [3.34] 115.63 (100.34–136.05) [8.77] 45.19 (36.48–51.69) [9.35] 1.19 3.04
13 350.18 (258.31–511.58) [5.66] >500; 0; 0 94.29 (67.32–126.43) [4.64] <0.7 3.71
Valproatee 483 287 209 1.7 2.3
a Dose (mg/kg) eliciting evidence of minimal neurological toxicity in 50 % of animals; 95 % confidence interval is shown in parentheses; the slope
regression line is shown in brackets
b Dose (mg/kg) eliciting the MES protection in 50 % animals
c Dose (mg/kg) eliciting the ScMet protection in 50 % animals
d Protective index—neurotoxic dose (median effective dose)
e Data from [40, 47]
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Fig. 3 cAMP accumulation studies in CHO cells expressing the hu-
man adenosine A2A receptor. The dose–response curves for the NECA-
induced stimulation of cAMP accumulation were generated with
NECA in the absence or in the presence of two different concentrations
of 28 (a) or 35 (b). Graphs from two independent experiments
performed in duplicates with mean values ± SEM are shown. Both
investigated compounds shifted the concentration–response curve for
NECA in a parallel manner to the right, indicating competitive antag-
onism. Apparent Kb values were as follows: 1,510±20 nM (28) and
1,210±130 nM (35)
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those co-crystallized with xanthines: XAC (PDB code:
3REY) and caffeine (PDB code: 3RFM) are of great impor-
tance for our research. Analysis of the ligand binding mode,
observed in the crystals 3REY and 3RFM, compared to the
binding mode of an inverse agonist ZM241385 bound to A2A
AR (PDB codes: 3PWH [42] and 3EML [43]) indicates flex-
ibility of some amino acid side chains within the receptor
binding cleft. In particular, the side chain of Asn253 (6.55),
described as a crucial residue for ligand binding [44–46], in
3REY is rotated relative to other structures, e.g. 3RFM with
caffeine as a ligand. Nevertheless, in both crystal structures of
A2A AR co-crystallized with xanthines, the terminal amino
group of Asn253 (6.55) forms the hydrogen bond with the
same carbonyl group present in purinedione core of ligands.
Due to the structure and the size of synthesized molecules,
A2A AR-XAC (3REY) crystal seems to be the best choice as a
template for docking. To validate the utilized molecular
docking methods, XAC ligand was redocked to its X-ray
structure of A2A receptor. In case of simulation without any
constraints, the obtained highest ranked pose was distinct from
the one in the crystal; superposition of both conformations
gave a high RMSD value of 9.68 Å. In this pose, an imidazol
nitrogen atom of the ligand plays a role of an H-bond acceptor
involved in the contact with the distal amino group of Asn253
(6.55), while a phenyl ring is situated in the proximity of TM6
and ECL2. The docking was then repeated, setting the H-bond
interaction between Asn253 (6.55) and one out of carbonyl
groups of the ligand as a constraint. This time, the overlay with
the experimental binding mode was better (Fig. 4, RMSD=
4.53 Å). The superposition of phenylpurinedione cores was
almost perfect, giving an RMSD value of 0.42 Å, but calcu-
lated and experimental poses differ with orientation of a polar
tail of XAC. However, in the crystal structure, the position of
this flexible chain is not strictly fixed, as its electron density is
not complete [42]. The protocol including constrained H-bond
between a ligand and Asn253 (6.55) was chosen for further
docking simulations.
As an additional validation to the tested series of xan-
thines, the structure of caffeine was added and docked
together with the rest of the compounds. Docking simula-
tions of the set of all 30 compounds to both templates gave
results that can be grouped in three clusters according to the
calculated docking score values.
In the two first, highest ranked clusters, the obtained poses
adopt a reflected or rotated orientation of the heterocyclic core
compared to the XAC conformation from the crystal. In this
position, in both cases, the carbonyl group C2=O2 of the
purinedione interacts with a side chain amino group of
Asn253 (6.55), while C4=O4 either corresponds to the 2-
oxo fragment of XAC or points to the top of the receptor,
between side chains of Glu169 and Leu267 (7.32).
However, it can be noticed that in both cases of published
X-ray structures co-crystallized with xanthines, purinedione
core interacts with Asn253 (6.55) in a similar way, with the
same carbonyl oxygen atom (C4=O4) of the ligand, even if
Asn253 in this crystal acid adopts two different conformations
of the side chain. Taking into account positions of both XAC
and caffeine in the binding site, we can presume that the
synthesized tricyclic derivatives of xanthine would bind into
the A2A receptor in a similar mode (shown in Fig. 5a, b)
despite lower docking scores. For this reason, the conforma-
tions belonging to the first two clusters were rejected.
The third cluster is created by poses predicted for most of
the compounds including caffeine (Fig. 5a, b). Although
docking scores are lower than those for the two first sets, this
pose is in agreement with the position of the ligand XAC in
the crystal structure. The carbonyl group C4=O4 interacts
here with the terminal amino group of Asn253 (6.55), and
the whole purinedione core of the modelled xanthines overlies
the heterocyclic part of XAC with very good RMSD values
(from 0.39 to 0.93 Å, for caffeine 0.58 Å), making π–π
stacking with the aromatic part of Phe168. Two N-methyl
(or N-propyl) substituents point towards the bottom of the
binding site, likewise in case of XAC. The third annelated
ring is situated between Phe168 and Glu169 of ECL2 from
one side and Ile274 (7.39) and Met270 (7.35) from the other.
The alkyl chain is buried in a similar pocket of the binding site
to the phenoxy tail of XAC, in the long narrow cleft limited by
residues from top fragments of TM2 (Ala63 (2.61), Ile66
(2.64) and Ser67 (2.65)) and TM7 (Leu267 (7.32) and
Tyr271 (7.36)) as well as Tyr9 (1.35) (Fig. 5c).
The compounds 25 and 33, unsubstituted in the annelated
ring, were not successfully docked in this position, while long
alkyl chains in this position, branched or not, are easily adapted
in the groove created by TM2 and TM7. Similarly, longer
propyl fragments at 1- and 3-positions of 35 make hydropho-
bic contacts with residues Leu85 (3.33), Leu249 (6.51) and
Met177 (5.38) from one side and Ile66 (2.64), Ala81 (3.29)
and Val84 (3.32) from the other, increasing affinity to the
receptor relative to short methyl substituents (35 vs. 9).
Compounds 24 and 30 were not found among poses from
this cluster either—the most probable explanation is that
the linear structure of the triple bond in 24 or a double-
branched chain of 30 causes a steric clash with residues
forming the cleft.
The performed docking experiments did not explain in
detail the correlation between structure and A2A AR affinity
of the obtained xanthines. Nevertheless, it can be stated that
both the third annelated ring and alkyl chains as N-
substituents fit well to the A2A binding pocket, forming
additional interactions, and their presence has a big influ-
ence on the affinity to the adenosine receptors compared to
caffeine—non-selective weak A2A AR antagonist. The sim-
ilar effect is observed for two N-propyl substituents and the
phenyl ring of XAC, very potent adenosine receptor antag-
onist (35, Fig. 5b).
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In vivo tests
Unsubstituted pyrimido- (5) and diazepinopurinedione
(25) did not show protective activity in both electric
and chemical seizures (Table 4). Introduction of N-alkyl
substituents resulted in anticonvulsant activity in the
pyrimidopurinediones, whereas these modifications did not
affect in the same way the group of diazepinopurinediones
as only compounds 31 and 32 showed protective activity in a
dose of 300 mg/kg, but after 4 h caused death of tested
animals. Probably, enlargement of the annelated ring in the
xanthine derivatives is not favourable for anticonvulsant ac-
tivity. Unsaturated substituents introduced into the tricyclic
xanthine derivatives (23 and 24) were also disadvantageous.
Generally, N-alkyl derivatives showed good protective activ-
ity in mice (i.p.), especially in ScMet test in short time (0.5 h).
The best compound was N-hexylpyrimidopurinedione 11,
with 100 % protection at a dose of 100 mg/kg with no
symptoms of neurotoxicity. The other two compounds with
long lipophilic chains 18 and 19 also showed good protection:
derivative 19was active in both tests, and ligand 18 displayed
protection in ScMet test. Both compounds did not show
neurotoxicity. The N-butyl and N-pentyl derivatives 9
and 10 displayed protective properties in MES and
ScMet tests but at the same time showed neurotoxicity.
Compounds with short chains (6, 7, 8 and 14) caused
death of test animals. The most toxic substance was N-
propargylpyrimidopurinedione 24, causing death follow-
ing clonic seizures and tonic extension.
The most active compounds in mice were also exam-
ined for activity in rats after oral administration, show-
ing higher seizure protection (Table 5). The best
compound was the butyl derivative 9, showing 100 %
protection in ScMet test in the dose of 50 mg/kg in
short time (0.25 and 0.5 h) and 50 % protection in dose
of 10 mg/kg after 1 2 and 4 h. Ligand 16 was active in
MES test at 30 mg/kg and in ScMet test at 50 mg/kg.
No symptoms of neurotoxicity were observed in both
tested compounds. Ligand 9 was also tested in a hippo-
campal kindled seizure screen (Table 6). Results suggest
the ability of 9 to prevent or modify fully kindled
seizures. The N-butyl and N-isobutyl derivatives 9 and
13 were advanced for phase II of evaluation for quan-
tification of activities (ED50 and TD50) against MES-
and ScMet-induced seizures in mice (i.p.) (Table 7).
These pharmacological parameters were compared with
data for valproate [40, 47]. Both tested substances were
characterized by a PIScMet higher than that of valproate,
but a lower PIMES.
The anticonvulsant activity of the examined compounds
was analysed for correlation with AR affinity. Some coinci-
dence of adenosine A2A affinity and anticonvulsant activity
was observed. Compounds showing anticonvulsant activity in
ScMet test (9, 11, 13, 14, 15, 16 and 18) were among the
Fig. 4 Superposition of the
XAC ligand from 3REY crystal
structure (purple) and redocked
pose of XAC (orange)
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Fig. 5 a The model of compound 9 (orange) docked to 3REY crystal
structure (chosen residues in green and XAC ligand in purple). b The
model of compound 35 (orange) docked to 3REY crystal structure
(chosen residues in green and XAC ligand in purple). c Superposition
of XAC ligand (purple) and compound 9 (orange) in the binding site of
A2A receptor
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pyrimidinepurinedione derivatives showing affinity towards
A2A AR. However, there were also compounds showing anti-
convulsant activity but were devoid of A2A AR affinity. The
most active A2A AR ligand, the diazepine derivative 28 and the
dipropyl derivative 35 were not active as anticonvulsants.
Comparing in vitro and in vivo activities of the studied
tricyclic xanthine derivatives, there is no clear correla-
tion between A1/A2A AR affinity and anticonvulsant
activity of the investigated ligands. So our previous
observation that A2A selectivity of AR antagonists may
be important for anticonvulsant activity has not been
confirmed in the present study [19].
Conclusions
Tricyclic pyrimido- and diazepinopurinediones are mod-
erately potent A1 and A2A AR antagonists. Enlargement
of the annelated ring caused an increase in affinity but
not selectivity. Pyrimidopurinodiones showed anticon-
vulsant activity in mice (i.p.) and rats (p.o.), but lower
homologs were toxic. Enlargement of the annelated ring
was unprofitable for anticonvulsant activity and led
practically to a lack of the activity. Although there is
no apparent correlation between anticonvulsant activity
and adenosine receptor affinity, it seems that a lipophilic
substituent is necessary for both activities.
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Appendix
Experimental section
Chemistry
Melting points were determined on a MEL-TEMP II appa-
ratus, and they are uncorrected. IR spectra were taken as
KBr discs on an FT Jasco IR 410 spectrometer. 1H-NMR
spectra (in CDCl3) for compounds 10, 13, 14 and 22 were
obtained at ambient temperature with a Bruker VM 250, for
other compounds with a Varian Mercury 300-MHz spec-
trometer, using signal of undeuterated solvent as an internal
standard. UV spectra were recorded on a Jasco UV/Vis V-
530 apparatus in 10−5 mole/L in methanol. Elemental anal-
yses (CHN) were performed on an Elementar Vario-EL III
apparatus and agreed with theoretical values within ±0.4 %.
TLC data were obtained with Merck silica gel 60 F254
aluminium sheets with benzene: acetone (7:3) as developing
system. Spots were detected under UV light. Syntheses of
compounds 5, 25 and 33 were described elsewhere [25, 26].
Synthetic procedures and analytical data of tricyclic
alkylimidazo-, pyrimido- and diazepinopurinediones
General procedure for the synthesis of 9-substituted 1,3-
dimethyl-6,7,8,9-tetrahydropyrimido[2,1- f]purine-
2,4(1H,3H)-dione (6–19, 23, 24). A mixture of (0.66 g,
2 mmol) of 7-(3-chloropropyl)-8-bromotheophylline (2)
and amine derivative (4–66 mmol) was heated under reflux
in the appropriate solvent (ethanol, propanol, butanol and
DMF) or without solvent for 5 to 15 h. After cooling, the
precipitate was separated. If the crude compound included a
li t t le amount of unreacted 7-(3-chloropropyl)-8-
bromotheophylline (monitoring by TLC), it was purified by
dissolving in 10 % HCl, alkalizing to pH8 with 10 % NaOH
and washing with water. If DMF was used as a reaction
medium, the product was precipitated by adding water to the
reaction mixture. Compound 17 did not crystallize after
cooling and was obtained by removing the excess of 2-
propynylamine by steam distillation and cooling the water
solution. All compounds were purified by crystallization.
1,3,9-Trimethyl-6,7,8,9-tetrahydropyrimido
[2,1-f]purine-2,4(1H,3H)-dione (6)
Reaction medium, ethanol; time of heating under reflux,
15 h; excess of amine, 33. Crystallization with ethanol gave
pure compound 6. Yield 47 %, mp 251–252 °C; TLC: Rf:
0.31; Anal. Calcd for C11H15O2N5 (6): C, 53.00; H, 6.07; N,
28.10. Found: C, 52.77; H, 5.91; N, 27.82. 1H-NMR δ
(ppm): 2.12–2.20 (m, 2H, N5CH2CH2CH2N9), 3.12 (s, 3H,
CH3), 3.29–3.33 (m, 3H+2H, N3CH3+CH2N9), 3.48 (s, 3H,
N1CH3), 4.19 (t, J=6.04Hz, 2H, N5CH2). IR KBr (cm
−1):
2,950–2,871—CH2, 1,699—CO (2), 1,655 (4), 744—CH2.
UV λmax, logε: 300.5, 4.15.
9-Ethyl-1,3-dimethyl-6,7,8,9-tetrahydropyrimido[2,1-f]
purine-2,4(1H,3H)-dione (7)
Reaction medium, ethanol; time of heating under reflux, 5 h;
excess of amine, 29. Crystallization with ethanol (30 %)
gave pure compound 7. Yield 34 %, mp 215–216 °C; TLC:
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Rf: 0.49; Anal. Calcd for C12H17O2N5 (7): C, 54.74; H,
6.52; N, 26.60. Found: C, 55.00; H, 6.52; N, 26.25. 1H-
NMR δ (ppm): 21.22 (t, J=7.14 Hz, 3H, CH2CH3), 2.13–
2.20 (m, 2H, N5CH2CH2CH2N9), 3.34–3.37 (m, 3H+2H,
N3CH3+CH2N9), 3.50 (s, 3H, N1CH3), 3.54–3.63 (m, 2H,
CH2CH3), 4.20 (t, J=6.04 Hz, 2H, N5CH2). IR KBr (cm
−1):
2,967–2,872—CH2, 1,697—CO (2), 1,666 (4), 784—CH2.
UV λmax, logε: 301.5, 4.28.
1,3-Dimethyl-9-propyl-6,7,8,9-tetrahydropyrimido[2,1-f]
purine-2,4(1H,3H)-dione (8)
Reaction medium, ethanol; time of heating under reflux, 5 h;
excess of amine, 12. Crystallization with ethanol (30 %)
gave pure compound 8. Yield 60 %, mp 188–190 °C; TLC:
Rf: 0.52; Anal. Calcd for C13H19O2N5 (8): C, 56.31; H, 6.91;
N, 21.25. Found: C, 56.25; H, 6.97; N, 24.96. 1H-NMR δ
(ppm): 0.95 (t, J=7.42 Hz, 3H, CH2CH3), 1.60–1.83 (m, 2H,
CH2CH2CH3), 2.11–2.19 (m, 2H, N5CH2CH2CH2N9), 3.34–
3.46 (m, 3H+2H, N3CH3+CH2N9), 3.49–3.59 (m, 2H+3H,
CH2CH3+N1CH3), 4.21 (t, J=5.91 Hz, 2H, N5CH2). IR KBr
(cm−1): 2,958–2,871—CH2, 1,697—CO (2), 1,664 (4), 784—
CH2. UV λmax, logε: 302, 4.34.
9-Butyl-1,3-dimethyl-6,7,8,9-tetrahydropyrimido[2,1-f]
purine-2,4(1H,3H)-dione (9)
Reaction medium, solvent-free; time of heating under re-
flux, 5 h; excess of amine, 15. Crystallization with ethanol
gave pure compound 9. Yield 81 %, mp 174–176 °C; TLC:
Rf: 0.37; Anal. Calcd for C14H21O2N5 (9): C, 57.71; H,
7.27; N, 24.04. Found: C, 57.63; H, 7.08; N, 23.84. 1H-
NMR δ (ppm): 0.95 (t, J=7.28 Hz, 3H, (CH2)3CH3),1.31–
1.38 (m, 2H, CH2CH3), 1.54–1.62 (m, 2H, CH2CH2CH3),
2.09–2.17 (m, 2H, N5CH2CH2CH2N9), 3.31–3.34 (m, 3H+
2H, N3CH3+CH2N9), 3.48–3.53 (m, 2H+3H, CH2CH3+
N1CH3), 4.19 (t, J=6.04 Hz, 2H, N5CH2). IR KBr (cm
−1):
2,958–2,873—CH2, 1,702—CO (2), 1,666 (4), 784—CH2.
UV λmax, logε: 302, 4.25.
1,3-Dimethyl-9-pentyl-6,7,8,9-tetrahydropyrimido[2,1-f]
purine-2,4(1H,3H)-dione (10)
Reaction medium, solvent-free; time of heating under re-
flux, 5 h; excess of amine, 20. Crystallization with ethanol
(80 %) gave pure compound 10. Yield 59 %, mp 183–185 °C;
TLC: Rf: 0.43; Anal. Calcd for C15H23O2N5 (10): C,
58.99; H, 7.60; N, 22.93. Found: C, 58.76; H, 7.26; N,
23.08. 1H-NMR δ (ppm): 0.92 (t, J=6.25 Hz, 3H,
(CH2)4CH3), 1.27–1.65 (m, 6H, (CH2)3CH3), 2.10–2.19
(m, 2H, N-CH2CH2CH2N9), 3.33–3.37 (m, 3H+2H,
N3CH3+CH2N9), 3.46–3.54 (m, 2H+3H, CH2CH3+
N1CH3), 4.24 (t, J=6.25 Hz, 2H, N5CH2). IR KBr
(cm−1): 2,952–2,869—CH2, 1,699—CO (2), 1,662 (4),
784—CH2. UV λmax, logε: 301, 4.34.
9-Hexyl-1,3-dimethyl-6,7,8,9-tetrahydropyrimido[2,1-f]
purine-2,4(1H,3H)-dione (11)
Reaction medium, solvent-free; time of heating under re-
flux, 5 h; excess of amine, 12. Crystallization with ethanol
gave pure compound 11. Yield 57 %, mp 149 °C; TLC: Rf:
0.55; Anal. Calcd for C16H25O2N5 (11): C, 60.16; H, 7.89;
N, 21.93. Found: C, 60.13; H, 3.94; N, 22.04. 1H-NMR δ
(ppm): 0.90 (t, J=5.77 Hz, 3H, (CH2)5CH3), 1.33–1.64 (m,
8H, (CH2)4CH3), 2.11–2.18 (m, 3H+2H, N3CH3+CH2N9),
3.49–3.53 (m, 2H+3H, CH2CH3+N1CH3), 4.21 (t, J=
6,04 Hz, 2H, N5CH2). IR KBr (cm
−1): 2,952–2869—CH2,
1,698—CO (2), 1,664 (4), 742—CH2. UV λmax, logε:
301.5, 4.32.
9-Isopropyl-1,3-dimethyl-6,7,8,9-tetrahydropyrimido[2,1-f]
purine-2,4(1H,3H)-dione (12)
Reaction medium, propanol; time of heating under reflux,
5 h; excess of amine, 12. Crystallization with ethanol (30 %)
gave pure compound 12. Yield 65 %, mp 241–242 °C; TLC:
Rf: 0.48; Anal. Calcd for C13H19O2N5 (12): C, 56.31; H,
6.91; N, 25.25. Found: C, 56.10; H, 6.58; N, 25.05. 1H-
NMR δ (ppm): 1.20 (d, J=6.86 Hz, 6H, CH(CH3)2), 2.05–
2.13 (m, 2H, N5CH2CH2CH2N9), 3.26 (s, 3H, N3CH3), 3.48
(s, 3H, N1CH3), 4.17 (t, J=6.04 Hz, 3H, N1CH3), 4.62–4.71
(m, 1H, N9CH). IR KBr (cm
−1): 2,967–2,848—CH2, 1,704—
CO (2), 1,662 (4), 742—CH2. UV λmax, logε: 302, 4.29.
9-Isobutyl-1,3-dimethyl-6,7,8,9-tetrahydropyrimido[2,1-f]
purine-2,4(1H,3H)-dione (13)
Reaction medium, solvent-free; time of heating under re-
flux, 5 h; excess of amine, 25. Crystallization with ethanol
(50 %) gave pure compound 13. Yield 68 %, mp 213–215 °C;
TLC: Rf: 0.44; Anal. Calcd for C14H21O2N5 (13): C,
57.71; H, 7.27; N, 24.04. Found: C, 58.05; H, 6.99; N,
23.79. 1H-NMR δ (ppm): 0.94 (d, J=6.50 Hz, 6H,
CH(CH3)2), 2.01–2.19 (m, 1H+ 2H, CH(CH3)2 +
N5CH2CH2CH2N9), 3.31–3.37 (m, 2H+2H, CH2N9CH2),
3.39 (s, 3H, N3CH3), 3.50 (s, 3H, N1CH3), 4.22 (t, J=
6.00 Hz, 2H, N5CH2). IR KBr (cm
−1): 2,964–2,844—
CH2, 1,698—CO (2), 1,662 (4), 742—CH2. UV λmax,
logε: 301.5, 4.34.
9-Sec-butyl-1,3-dimethyl-6,7,8,9-tetrahydropyrimido[2,1-f]
purine-2,4(1H,3H)-dione (14)
Reaction medium, solvent-free; time of heating under re-
flux, 5 h; excess of amine, 25. Crystallization with ethanol
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(50 %) gave pure compound 14. Yield 98 %, mp 188–190 °C;
TLC: Rf: 0.48; Anal. Calcd for C14H21O2N5 (14): C,
57.71; H, 7.27; N, 24.04. Found: C, 57.90; H, 7.43; N,
23.87. 1H-NMR δ (ppm): 0.90 (t, J=7.38 Hz, 3H,
CH2CH3), 1.19 (d, J=6.60 Hz, 3H, =CHCH3), 2.06–
2.16 (m, 2H, N5CH2CH2CH2N9), 3.22–3.27 (m, 2H,
CH2N9), 3.37 (s, 3H, N3CH3), 3.50 (s, 3H, N1CH3),
4.18–4.24 (m, 2H, N5CH2), 4.39–4.48 (m, 1H, N1CH=).
IR KBr (cm−1): 2,969–2875—CH2, 1,704—CO(2), 1,652
(4), 744—CH2. UV λmax, logε: 302.5, 4.26.
1,3-Dimethyl-9-(pentan-2-yl)-6,7,8,
9-tetrahydropyrimido[2,1-f]purine-2,4(1H,3H)-dione (15)
Reaction medium, DMF; time of heating under reflux, 10 h;
excess of amine, 4. Crystallization with ethanol/H2O gave
pure compound 15. Yield 91 %, mp 143–144 °C; TLC: Rf:
0.65; Anal. Calcd for C15H23O2N5 (15): C, 59.00; H, 7.60;
N, 22.94. Found: C, 58.90; H, 7.57; N, 22.99. 1H-NMR δ
(ppm): 0.93 (t, J=7.29 Hz, 3H, CH2CH3), 1.17 (d, J=
6.88 Hz, 3H, CH3CH), 1.25–1.59 (m, 4H, CH2CH2CH3),
2.05–2.13 (m, 2H, N5CH2CH2CH2N9), 3.20–3.25 (m, 2H,
CH2N9), 3.35 (s, 3H, N3CH3), 3.50 (s, 3H, N1CH3), 4.18–
4.24 (m, 2H, N5CH2), 3.49 (s, 3H, N1CH3), 4.14–4.24 (m,
2H, N5CH2), 4.51–4.58 (m, 1H, N1CH=). IR KBr (cm
−1):
2,963–2,872—CH2, 1,697—CO (2), 1,666 (4), 743—CH2.
UV λmax, logε: 302, 4.28.
1,3-Dimethyl-9-(4-methylpentan-2-yl)-6,7,8,
9-tetrahydropyrimido[2,1-f]purine-2,4(1H,3H)-dione (16)
Reaction medium, DMF; time of heating under reflux, 5 h;
excess of amine, 2. Crystallization with ethanol/H2O gave
pure compound 16. Yield 59 %, mp 116–117 °C; TLC: Rf:
0.58; Anal. Calcd for C16H25O2N5 (16): C, 60.16; H, 7.89; N,
21.93. Found: C, 60.22; H, 8.01; N, 21.96. 1H-NMR δ (ppm):
0.89–0.94 (m, 6H, CH(CH3)2), 1.15 (d, J=6.60 Hz, 3H,
N9CHCH3), 1.19–1.26 (m, 1H, CH(CH3)2), 1.40–1.58 (m,
2H, CH2CH(CH3)2), 2.03–2.15 (m, 2H, N5-CH2-CH2-CH2-
N9), 3.14–3.20 (m, 2H, CH2N9), 3.33 (s, 3H, N3CH3), 3.47
(s, 3H, N1CH3), 4.12–4.22 (m, 2H, N5CH2), 4.57–4.67 (m,
1H, N9CHCH3). IRKBr (cm
−1): 2,952–2,867—CH2, 1,699—
CO (2), 1,660 (4), 742—CH2. UV λmax, logε: 301.5, 4.21.
1,3-Dimethyl-9-(2-methylhexyl)-6,7,8,
9-tetrahydropyrimido[2,1-f]purine-2,4(1H,3H)-dione (17)
Reaction medium, DMF; time of heating under reflux, 5 h;
excess of amine, 4. Crystallization with ethanol/H2O gave
pure compound 17. Yield 81 %, mp 122–124 °C; TLC: Rf:
0.63; Anal. Calcd for C17H27O2N5 (17): C, 61.24; H, 8.17; N,
21.01. Found: C, 61.51; H, 8.19; N, 21.12. 1H-NMR δ (ppm):
0.84–0.89 (m, 6H, 2CH3), 1.18–1.59 (m, 8H, CH2 CH(CH2)3
CH2CH3), 1.40–1.58 (m, 2H, CH2CH(CH3)2), 2.06–2.13 (m,
2H, N5CH2CH2CH2N9), 3.17–3.21 (m, 2H, CH2N9), 3.36 (s,
3H, N3CH3), 3.48 (s, 3H, N1CH3), 4.21 (t, J=6.05 Hz, 2H,
N5CH2), 4.29–4.35 (m, 1H, N9CH). IR KBr (cm
−1): 2,960–
2,861—CH2, 1,699—CO (2), 1,659 (4), 750—CH2. UV
λmax, logε: 302, 4.31.
9-(Heptan-2-yl)-1,3-dimethyl-6,7,8,
9-tetrahydropyrimido[2,1-f]purine-2,4(1H,3H)-dione (18)
Reaction medium, DMF; time of heating under reflux, 10 h;
excess of amine, 2. Crystallization with ethanol/H2O gave
pure compound 18. Yield 57 %, mp 94–96 °C; Anal. Calcd
for C17H27O2N5 (18): C, 61.24; H, 8.17; N, 21.01. Found: C,
60.95; H, 7.90; N, 21.05. 1H-NMR δ (ppm): 0.84–0.94 (m, 3H,
(CH2)4-CH3), 1.17 (d, J=6.87 Hz, 3H, CHCH3), 1.26–1.59
(m, 8H, (CH2 )4CH3), 2.05–2.13 (m, 2H, N5CH2CH2CH2N9),
3.20–3.25 (m, 2H, CH2N9), 3.35(s, 3H, N3CH3), 3.49 (s, 3H,
N1CH3), 4.13–4.24 (m, 2H, N5CH2), 4.50–4.56 (m, 1H,
N9CH). IR KBr (cm
−1): 2,955–2,859—CH2, 1,701—CO (2),
1,656 (4), 745—CH2. UV λmax, logε: 302, 4.30.
1,3-Dimethyl-9-(6-methylheptan-2-yl)-6,7,8,
9-tetrahydropyrimido[2,1-f]purine-2,4(1H,3H)-dione (19)
Reaction medium, DMF; time of heating under reflux, 5 h;
excess of amine, 2. Crystallization with ethanol/H2O gave pure
compound 19. Yield 60 %, mp 99–101 °C; TLC: Rf: 0.48;
Anal. Calcd for C18H29O2N5 (19): C, 61.24; H, 8.17; N, 21.01.
Found: C, 61.99; H, 8.21; N, 20.19. 1H-NMR δ (ppm): 0.83–
0.86 (m, 6H, CH(CH3)2), 1.18 (d, J=6.87Hz, 3H, N9CHCH3),
1.23–1.38 (m 1H CH(CH3)2), 1.43–1.61(m, 6H, (CH2)3),
2.06–2.14 (m, 2H, CH2N9), 3.36 (s, 3H, N3CH3), 3.50
(s, 3H, N1CH3), 4.12–4.27 (m, 2H, N5CH2), 4.46–4.58 (m,
1H, N9CHCH3). IR KBr (cm
−1): 2,956–2,858—CH2, 1,708—
CO (2), 1,651 (4), 742—CH2. UV λmax, logε: 302.5, 4.25.
9-Allyl-1,3-dimethyl-6,7,8,9-tetrahydropyrimido[2,1-f]
purine-2,4(1H,3H)-dione (23)
Reaction medium, solvent-free; time of heating under re-
flux, 5 h; excess of amine, 20. Crystallization with ethanol
(10 %) gave pure compound 23. Yield 65 %, mp 157–159 °C;
TLC: Rf: 0.35; Anal. Calcd for C13H17O2N5 (23): C,
56.71; H, 6.22; N, 24.44. Found: C, 56.88; H, 6.48; N,
25 . 12 . 1H-NMR δ ( ppm) : 2 . 10–2 .18 (m , 2H ,
N5CH2CH2CH2N9), 3.29 (t, J=5.65 Hz, 2H, CH2N9),
3.34 (s, 3H, N3CH3), 3.48 (s, 3H, N1CH3), 4.16 (t, J=
6.04 Hz, 2H, N9CH2), 4.20 (t, J=6.04 Hz, 2H, N5CH2),
5.20–5.26 (m, 2H, CH2=CH), 5.75–5.88 (m, 1H, CH2=
CH). IR KBr (cm−1): 3,081—CH2-CH=CH2, 2,944–
2,902 CH2, 1,695—CO (2), 1,664 (4), 750—CH2. UV
λmax, logε: 303.5, 4.30.
Purinergic Signalling (2013) 9:395–414 409
1,3-Dimethyl-9-(prop-2-ynyl)-6,7,8,
9-tetrahydropyrimido[2,1-f]purine-2,4(1H,3H)-dione (24)
Reaction medium, n-butanol; time of heating under reflux,
10 h; excess of amine, 5. Crystallization with ethanol (30 %)
gave pure compound 24. Yield 93 %, mp 203–206 °C; TLC:
Rf: 0.57; Anal. Calcd for C13H15O2N5 (24): C, 57.14; H,
5.54; N, 25.62. Found: C, 57.44; H, 5.66; N, 25.79. 1H-
NMR δ (ppm): 2.18–2.29 (m, 3H, N5CH2CH2CH2+CH≡),
3.35 (s, 3H, N3CH3), 3.35–3.42 (m, 2H, CH2N9), 3.50 (s,
3H, N1CH3), 4.36 (t, J=6.05 Hz, 2H, N9CH2). IR KBr
(cm−1): 3,123—CH2-CH=CH2, 2,952—CH2, 1,701—CO
(2), 1,665 (4), 744—CH2. UV λmax, logε: 296, 4.19.
Synthesis of 9-ethenyl 1,3-dimethyl-6,7,8,
9-tetrahydropyrimido[2,1-f]purine-2,4(1H,3H)-dione (22)
A mixture of 9-(2-bromoethyl)-1,3-dimethyl-6,7,8,9-
tetrahydropyrimido[2,1-f]purine-2,4(1H, 3H)-dione (0.68 g,
2 mmol) (21) [27] and KOH (0.11 g, 2 mmol) in 10 ml ethanol
was heated at reflux for 20 h. After cooling, the precipitate was
separated and washed with water and crystallized from
methoxyethanol. Yield 70 %, mp 268–271 °C; TLC: Rf: 0.55;
Anal. Calcd for C12H15O2N5 (22): C, 55.19; H, 5.79; N, 26.80.
Found: C, 55.47; H, 5.55; N, 26.45. 1H-NMR δ (ppm): 2.17–
2.28 (m, 2H, N5CH2CH2CH2N9), 3.38 (s, 3H, N3CH3), 3.53 (s,
3H, N1CH3), 3.54–3.59 (m, 2H, N9CH2), 4.26–4.52 (m, 4H,
N5CH2+CH2=), 7.38–7.48 (m, 1H, CH=). IR KBr (cm
−1):
3,108–3,089—CH=CH2, 2,983–2883 CH2, 1,701—CO (2),
1,652 (4), 746—CH2. UV λmax, logε: 304, 4.40.
General procedure for the synthesis of 10-substituted
1,3-dimethyl-6,7,8,9-tetrahydrodiazepino[2,1-f]purine-
2,4(1H,3H)-diones (26–32)
A mixture of 7-(4-bromobutyl)-8-bromotheophylline
(0.79 g, 2 mmol) (3) [23] and an amine derivative (4–
72 mmol) was heated under reflux without solvent or with
ethanol, isobutanol or DMF for 5–10 h. Compounds 30 and
31 precipitated by adding water to the reaction mixture;
compounds 26 and 27 were obtained by removing the
solvent and excess of amine by distillation under reduced
pressure and adding water to the residue. Compounds 28, 29
and 32 precipitated by removing the excess of amine by
steam distillation and cooling the water solution. All com-
pounds were purified by crystallization from diluted ethanol
or by dissolving in ethanol and precipitation with water.
10-Ethyl-1,3-dimethyl-6,7,8,9-tetrahydrodiazepino[2,1-f]
purine-2,4(1H,3H)-dione (26)
Reaction medium, ethanol; time of heating under reflux,
10 h; excess of amine, 36. Crystallization with ethanol
(30 %) gave pure compound 26. Yield 38 %, mp 124–
125 °C; TLC: Rf: 0.62; Anal. Calcd for C13H19O2N5 (26):
C, 56.29; H, 6.91; N, 25.24. Found: C, 56.08; H, 6.64; N,
25.50. 1H-NMR δ (ppm): 1.22–1.26 (t, J=7.01 Hz, 3H,
CH3CH2), 1.27–1.92 (s, 4H, N5CH2(CH2)2CH2), 3.30–
3.23 (m, 2H, CH2CH3), 3.37 (s, 3H, N3CH3), 3.51 (s, 3H,
N1CH3), 3.54–3.56 (m, 2H, CH2N10), 4.28–4.31 (m, 2H,
N5CH2). IR KBr (cm
−1): 2,952–2873—CH2, 1,693—
CO(2), 1,661 (4), 740—CH2. UV λmax, logε: 300, 4.22.
1,3-Dimethyl-10-propyl-6,7,8,9-tetrahydrodiazepino[2,1-f]
purine-2,4(1H,3H)-dione (27)
Reaction medium, isobutanol; time of heating under reflux,
10 h; excess of amine, 11. Crystallization with ethanol
(30 %) gave pure compound 27. Yield 46 %, mp 153–
154 °C; TLC: Rf: 0.64; Anal. Calcd for C14H21O2N5 (27):
C, 57.71; H, 7.27; N, 24.03. Found: C, 57.76; H, 6.98; N,
23.66. 1H-NMR δ (ppm): 0.91 (t, J=7.43 Hz, 3H,
(CH2)2CH3), 1.57–1.73 (m, 2H, CH2CH2CH3), 1.87–1.91
(m, 4H, N5CH2(CH2)2CH2N10), 3.24 (t, J=5.45 Hz, 2H,
CH2CH2CH3), 3.37 (s, 2H, N3CH3), 3.42–3.47 (s, 2H,
CH2N10), 3.51 (s, 3H, N1CH3), 4.31 (t, J=5.08 Hz, 2H,
N5CH2). IR KBr (cm
−1): 2,935–2870—CH2, 1,692—
CO(2), 1,653 (4), 750—CH2. UV λmax, logε: 300, 4.30.
10-Butyl-1,3-dimethyl-6,7,8,9-tetrahydrodiazepino[2,1-f]
purine-2,4(1H,3H)-dione (28)
Reaction medium, solvent-free; time of heating under re-
flux, 5 h; excess of amine, 25. Crystallization with
ethanol/H2O gave pure compound 28. Yield 72 %, mp 84–
86 °C; TLC: Rf: 0.70; Anal. Calcd for C15H23O2N5 (28): C,
58.99; H, 7.60; N, 22.93. Found: C, 58.89; H, 7.22; N,
22.60. 1H-NMR δ (ppm): 0.95 (t, J=7.28 Hz, 3H,
(CH2)3CH3), 1.30–1.42 (m, 2H, CH2CH2CH2CH3), 1.57–
1.67 (m, 2H, CH3CH2CH2CH3), 1.87–1.88 (m, 4H
N5CH2(CH2)2CH2N10), 3.23 (t, J=5.01 Hz, 2H N10CH2),
3.37 (s, 3H, N3CH3), 3.48 (t, J=7.48 Hz, 2H, CH2N10), 3.51
(s, 3H, N1CH3), 4.30 (t, J=5.09 Hz, 2H, N5CH2). IR KBr
(cm−1): 2,957–2,871—CH2, 1,700—CO(2), 1,658 (4),
745—CH2. UV λmax, logε: 300, 4.28.
10-Sec-butyl-1,3-dimethyl-6,7,8,9-tetrahydrodiazepino
[2,1-f]purine-2,4(1H,3H)-dione) (29)
Reaction medium, solvent-free; time of heating under re-
flux, 10 h; excess of amine, 10. Crystallization with ethanol
(50 %) gave pure compound 29. Yield 57 %, mp 138–140 °C;
TLC: Rf: 0.53; Anal. Calcd for C15H23O2N5 (29): C,
58.99; H, 7.60; N, 22.93. Found: C, 58.67; H, 7.30; N,
22.75. 1H-NMR δ (ppm): 0.95 (t, J=1.10 Hz, 3H,
CH2CH3), 1.22 (d, J=7.60 Hz, 3H, CHCH3), 1.45–1.72
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( m , 2 H , C H 3 C H 2 ) , 1 . 7 2 – 2 . 0 0 ( m , 4 H ,
N5CH2(CH2)2CH2N10), 2.98–3.28 (m, 2H, CH2 N10), 3.37
(s, 2H, N3CH3), 3.48 (t, J=7.48Hz, 2H, CH2N10), 3.51 (s, 3H,
N1CH3), 4.01–4.12 (m, 2H, N5CH2), 4.51–4.58 (m, 1H,
CHCH3). IR KBr (cm
−1): 2,966–2,876—CH2, 1,701—
CO(2), 1,660 (4), 745—CH2. UV λmax, logε: 300, 4.20.
1,3-Dimethyl-10-(4-methylpentan-2-yl)-6,7,8,
9-tetrahydrodiazepino[2,1-f]purine-2,4(1H,3H)-dione (30)
Reaction medium, DMF; time of heating under reflux, 10 h;
excess of amine, 2. Crystallization with ethanol/H2O gave
pure compound 30. Yield 61 %, mp 96–100 °C; TLC: Rf:
0.72; Anal. Calcd for C17H27O2N5 (30): C, 61.22; H, 8.17; N,
21.02. Found: C, 61.52; H, 8.09; N, 20.90. 1H-NMR δ (ppm):
0.92–0.94 (m, 6H, CH(CH3)2), 1.19–1.28 (m, 4H CHCH3+
CH(CH3)2), 1.50–1.67 (m, 2H, CH2CH), 1.73–1.97 (m, 4H,
N5CH2(CH2)2CH2N10), 2.99–3.27(m, 2H, CH2N10), 3.36 (s,
3H, N3CH3), 3.50 (s, 3H, N1CH3), 4.02–4.10 (m, 1H,
N5CH), 4.27–4.34 (m, 2H, N5CH2), 4.48–4.55 (m, 1H,
N10CH). IR KBr (cm
−1): 2,946–2,876—CH2, 1,695—
CO(2), 1,664 (4), 747—CH2. UV λmax, logε: 300, 4.37.
1,3-Dimethyl-10-(pentan-2-yl)-6,7,8,
9-tetrahydrodiazepino[2,1-f]purine-2,4(1H,3H)-dione (31)
Reaction medium, DMF; time of heating under reflux, 10 h;
excess of amine, 2. Crystallization with ethanol/H2O gave
pure compound 31. Yield 78 %, mp 113–115 °C; TLC: Rf:
0.70; Anal. Calcd for C16H25O2N5 (31): C, 60.17; H, 7.90;
N, 21.93. Found: C, 60.19; H, 7.85; N, 21.78. 1H-NMR δ
(ppm): 0.90–0.94 (m, 3H, CH2CH3), 1.21 (d, J=6.88 Hz,
3H, CHCH3), 1.32–1.64 (m, 4H, (CH2)2CH3), 1.74–1.98
(m, 4H, N5CH2(CH2)2CH2N10), 2.99–3.07 (m, 1H,
CH2N10), 3.20–3.28 (m, 1H, CH2N10), 3.50 (s, 3H,
N1CH3), 4.01–4.09 (m, 1H, N5CH), 4.17–4.24 (m, 2H,
N5CH2), 4.49–4.57 (m, 1H, N10CH). IR KBr (cm
−1):
2,949–2,871—CH2, 1,700—CO(2), 1,661 (4), 745—CH2.
UV λmax, logε: 300, 4.29.
10-Allyl-1,3-dimethyl-6,7,8,9-tetrahydrodiazepino[2,1-f]
purine-2,4(1H,3H)-dione (32)
Reaction medium, solvent-free; time of heating under re-
flux, 5 h; excess of amine, 20. Crystallization with
ethanol/H2O gave pure compound 32. Yield 65 %, mp
228–230 °C; TLC: Rf: 0.62; Anal. Calcd for C17H25O2N5
(32): C, 58.11; H, 6.63; N, 24.20. Found: C, 58.23; H, 6.48;
N, 24.36. 1H-NMR δ (ppm): 1.83–1.90 (m, 4H,
N5CH2(CH2)2CH2N10), 3.15 (t, J=4.95 Hz, 2H, CH2N10),
3.37 (s, 3H, N3CH3), 3.51 (s, 3H, N1CH3), 4.07 (d, J=
4.95 Hz, 2H, N10CH2), 4.33 (t, J=4.95 Hz, 2H, N5CH2),
5.21–5.30 (m, 2H, CH2=CH), 5.89–6.00 (m, 1H, CH2=CH).
IR KBr (cm−1): 3,078–3,010—allyl, 2,936—CH2, 1,696—
CO(2), 1,652 (4), 750—CH2. UV λmax, logε: 298, 4.23.
8-Isopropyl-1,3-dimethyl-6,7-dihydro-1H-imidazo[2,1-f]
purine-2,4(1H,3H)-dione (34)
A mixture of (0.73 g, 2 mmol) of 7-(2-bromoethyl)-8-
bromotheophylline (1) [16, 21] and isopropyl amine (1.42 g,
24 mmol) was heated under reflux for 5 h. After cooling, the
precipitate was separated and crystallized from 30 % ethanol
to give analytically pure compound 34. Yield 50 %, mp 157–
159 °C; Anal. Calcd for C12H17O2N5 (34): C, 54.74; H, 6.50;
N, 26.60. Found: C, 54.35; H, 6.50; N, 26.28. 1H-NMR δ
(ppm): 1.83–1.90 (m, 4H, N5CH2(CH2)2CH2N10), 3.15 (t, J=
4.95 Hz, 2H, CH2N10), 3.37 (s, 3H, N3CH3), 3.51 (s, 3H,
N1CH3), 4.07 (d, J=4.95 Hz, 2H, N10CH2), 4.33 (t, J=
4.95 Hz, 2H, N5CH2), 5.21–5.30 (m, 2H, CH2=CH), 5.89–
6.00 (m, 1H, CH2=CH). IR KBr (cm
−1): 2,960–2,870—
CH2–, 1,696—CO(2), 1,653—CO (4), 749—CH2–. UV λmax,
logε: 302, 4.21.
9-Butyl-1,3-dipropyl-6,7,8,9-tetrahydropyrimido[2,1-f]
purine-2,4(1H,3H)-dione (35)
A mixture of (0.78 g, 2 mmol) of 1,3-dipropylo-7-(3-
chloropropyl)-8-bromo-purine-2,4(3H,6H)-dione (4) [16,
17] and butyl amine (2.20 g, 30 mmol) was heated under
reflux for 5 h. After cooling, the precipitate was separated
and crystallized from ethanol to give analytically pure com-
pound 35. Yield 45 %, mp 77–79 °C; Anal. Calcd for
C18H29O2N5×H2O (29): C, 59.14; H, 8.42; N, 19.16.
Found: C, 58.85; H, 8.81; N, 19.10. 1H-NMR δ (ppm):
0.91–0.98 (m, 8H, CH3CH2CH2+CH3-CH2CH2CH2),
1.28–1.41 (m, 6H, CH3CH2CH2N1+CH3CH2CH2CH2),
3.24 (t, J=5.64 Hz, 2H, N9-CH2 ), 3.52 (t, J=7.15Hz,
2H, N9-CH2), 3.89–3.98 (m, 4H, N1,N3CH2CH2CH3),
4.20 (t, J=5.19Hz, 2H, N5CH2). IR KBr (cm
−1):
3,518–2,870 H2O, 2,959–2,874—CH2–, 1,689—CO (2),
1,655—CO (4), 754—CH2–. UV λmax, logε: 303, 4.30.
Pharmacology
Adenosine receptor binding studies
[3H]CCPA (58 Ci/mmol) was purchased from NEN Life
Sciences; [3H]MSX-2 (84 Ci/mmol), [3H]PSB-11
(28 Ci/mmol) and [3H]PSB-603 (73 Ci/mmol) were
obtained from Quotient Biosciences (custom synthesis).
The non-radioactive precursors of [3H]MSX-2 (MSX-1)
[33, 48], [3H]PSB-11 (PSB-10) [36, 49] and [3H]PSB-603
(PSB-603) [35] were synthesized in our laboratory. Frozen
rat brains obtained from Pel Freez®, Rogers, AR, USA,
were dissected to obtain cortical membrane preparations
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for A1 assays and striatal membrane preparations for A2A
assays as described [50]. CHO cells stably transfected with
the human adenosine A1, A2B and A3 receptors were used
for membrane preparations as previously described [50, 51].
For A2A adenosine receptor assays, commercially available
membrane preparations containing the human A2A AR were
obtained from Perkin Elmer Life Sciences (Boston, MA,
USA). Stock solutions of the compounds were prepared in
dimethylsulfoxide (DMSO); the final concentration of
DMSO in the assays did not exceed 2.5 %. Initial screening
was performed at a single concentration of 25 or 10 μM,
depending on target receptor. Binding assays were
performed as previously described [33, 50–54]. Curves were
determined using six to seven different concentrations of
test compounds spanning three orders of magnitude. At least
three separate experiments were performed, each in tripli-
cate. For non-linear regression analysis, the Cheng–Prusoff
equation and KD values of 0.2 nM (rat A1) and 0.6 nM
(human A1), respectively, for [
3H]CCPA [34]; 8 nM (rat
A2A) and 7 nM (human A2A), respectively, for [
3H]MSX-2
[33, 55]; 0.41 nM (human A2B) for [
3H]PSB-603 (human
A2B) [35] and 4.9 nM (human A3) for [
3H]PSB-11 [52] were
used to calculate Ki values from IC50 values.
Anticonvulsant screening
The anticonvulsant evaluation was carried but using
reported procedures [39, 40, 47]. Male albino mice
(Carworth Farms Nr 1, 18–25 g) and male albino rats
(Spraque-Dawley, 100–150 g) were used as experimental
animals. A group of three to five mice was used in MES and
ScMet tests, and a group of four to eight animals was used in
rotorod tests. For the evaluation of activity after oral admin-
istration, a group of four rats was used. The test compounds
were suspended in 0.5 % methylcellulose water mixture.
In the preliminary screening, each compound was admin-
istered as an i.p. injection at three dose levels (30, 100 and
300 mg/kg), with anticonvulsant activity and neurotoxicity
assessed at 30-min and 4-h intervals after administration.
For some compounds, also intervals of 15 min and 1 h were
used. Anticonvulsant efficacy was measured by MES,
ScMet and neurological deficit in the rotorod tests, and the
data are presented in Table 4. Some selected derivatives
were examined for oral activity in the MES and ScMet
and neurotoxicity screen (rotorod test) 30 and 50 mg/kg
doses. The results are summarized in Table 5.
The pharmacological parameters estimated in the prelim-
inary screening were quantified for compounds 9 and 13 in
mice (i.p.) (Table 7) and for comp. 9 also in rats (p.o.)
(Table 6).
Anticonvulsant activity was expressed in terms of the
median effective dose (ED50) MES and ScMet in mice and
ED50 ScMet in rats, and neurotoxicity was expressed as the
median toxic dose (TD50). For determination of ED50 and
TD50, groups of eight mice and rats were given a range of
i.p. or p.o. doses of the test drug until at least three points
were established in the range of 10–90 % seizure protection
or minimal observed neurotoxicity. From the plot of these
data, the respective ED50, TD50 value (95 %) confidence
intervals, slope of the regression line and the standard error
of the slope were calculated by a computer program based
on [38] methods described by Finney. For comp. 9, the
hippocampal kindling model of focal seizures was applied
(Table 6). In this procedure, the bipolar electrodes were
placed surgically in the ventral hippocampus of adult male
Spraque-Dawley rats. Stage five behavioural seizures are
produced by using a stimulus consisting of a 50-Hz, 10-s
train of 1-ms biphasic 200-μA pulses delivered every
30 min for 6 h. A single dose of comp. 9 is then adminis-
tered intraperitoneally, 15 min following the last stimula-
tion. The anticonvulsant activity of 9 is assessed every
30 min for 2 h, starting 15 min after administering the test
material. After each stimulation, seizure scores and after
discharge durations were recorded (Table 6).
Molecular modelling
The 3D molecule models of 5–35 and caffeine were built
using Schrödinger Maestro molecular modelling environ-
ment [56] basing on presented crystal structures of chosen
pyrimido- and diazepinopurinediones (10 and 30, respec-
tively). The geometry optimization was performed using the
multiple minimization method as implemented in
MacroModel with MMFF force field and Truncated Newton
Conjugate Gradient options and terminated when the root
means square (RMS) of conjugate gradient was below
0.05 kJmol−1Å−1. The minimization was carried out for
water solvent, with distance-dependent dielectric constant
as a way to treat electrostatic interactions.
The template 3REY was prepared to docking using the
Protein Preparation Wizard option as a part of Schrodinger
package. The ligand binding cavity was confined to a box
with the crystal ligand in the center (size of the box set
automatically), according to the receptor grid generation
procedure. The studies of docking to the rigid receptor
binding pocket were performed using Glide program, with
standard precision (SP) mode.
For validation, redocking of XAC ligand was done. After
initial docking, 10 poses for each ligand, with RMS devia-
tion higher than 0.5 Å, were kept, and post-minimized,
RMSD values between predicted and crystallographic posi-
tions of the ligand were calculated. Redocking of XAC was
performed twice: (1) without any constraints and (2)
with the amino hydrogen atom of the Asn253 (6.55)
side chain used as a constrained H-bond donor for a
carbonyl group of xanthine.
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Molecular docking of A2A AR antagonists
Docking simulations of low-energy conformations for all of
the synthesized compounds and caffeine were performed
with SP mode to both templates with limitation used during
redocking: the constrained H-bond between the side chain
amino group of Asn253 (6.55) and the ligand. Five poses
obtained after docking for each ligand (RMS deviation
higher than 0.5 Å) were post-minimized, and final poses
were kept and analysed according to the obtained docking
score values.
For the graphic presentation of the selected structures
with the highest docking scores, representing individual
clusters of poses, PyMOL [57] software was used.
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